Challenge
A mid-market PE fund had a letter of intent on a ₹2,800 crore Indian generic pharma company — a strong domestic chronic-care portfolio with a small US generics export business. The seller's EBITDA projection implied a 9.1x entry multiple, justified by a claimed 18% revenue CAGR from the US pipeline and domestic chronic growth.
The fund's investment committee had been burned twice before by India-pharma deals where "the pipeline was the story." Their question to us: "What is the true maintainable EBITDA — and what breaks between signing and day 100?"
Approach
We ran a three-track diligence over eight weeks:
Track 1 — Commercial diligence. Bottom-up revenue bridge for the domestic portfolio: molecule-level growth rates, price erosion (NLEM/DPCO impact), prescription analytics (IQVIA/EPRX-style data), and doctor-level share-of-voice analysis for the top 60 molecules (which comprised 68% of domestic revenue). For the US business: ANDA pipeline status, first-to-file opportunities, and channel concentration (wholesaler + GPO customer mapping).
Track 2 — Operational & regulatory diligence. Plant-level capacity and utilisation, cost-of-goods benchmarking, and a deep dive on regulatory history — including a USFDA warning letter at the flagship plant and two import alerts in the last 36 months.
Track 3 — Financial & tax diligence. Normalisation of one-offs, related-party transactions, channel inventory (secondary sales vs. primary), and contingent liabilities (litigation, export penalties).
Track 4 — 100-day plan build. We ran integration-scenario workshops with the target's CFO and plant heads to pressure-test synergy assumptions and identify day-1 risks.
Analysis
The domestic story was real — but softer than presented. Chronic therapy growth of 14% was genuine (diabetes, cardiac, respiratory), but the seller's forecast assumed zero NLEM price erosion on 40% of the portfolio; our base case applied 3.2% annual erosion on those molecules, cutting domestic EBITDA by ₹38 crore by year 3.
The US business was the valuation fulcrum. The seller's deck priced the US pipeline at ₹540 crore of forecast revenue by year 4. Our molecule-by-molecule screen found:
- 7 of 22 ANDAs were for molecules with 4+ competitors already — commodity pricing;
- the flagship plant's warning letter meant no US product launches from that site until remediation — a 14–20 month delay;
- one "anchor" product — 38% of the US forecast — faced a first-filer challenge with an 8-month exclusivity window that the seller's model had overstated to 18 months.
Net effect: US revenue forecast cut 41%, and total EBITDA forecast cut 22% (year-3: ₹412 crore vs. seller's ₹528 crore).
Working capital had a landmine: channel inventory at the distributor level was 11.2 weeks vs. 7-week industry norm — suggesting the seller had been "stuffing" the channel to hit the trailing EBITDA number. Adjusting for the pull-back, trailing EBITDA was ~9% lower than presented.
Findings
- True maintainable EBITDA was ₹238 crore vs. the presented ₹262 crore — an 9% adjustment before any growth debate.
- The US pipeline was an option, not an asset — worth 30–40% of the seller's ascribed value, with a remediation-linked trigger.
- The 100-day risk register surfaced three deal-breakers-in-waiting: key-man dependence (two R&D heads held the ANDA knowledge), a ₹62 crore related-party receivable that needed haircutting, and plant-level culture clash flagged by 60% of target middle managers in confidential interviews.
- The deal still worked at a revised price — at ≤8.2x adjusted EBITDA, the domestic chronic franchise alone supported the return thesis.
Recommendation
We recommended the fund renegotiate on the adjusted numbers, with structure:
- Price at ≤8.2x adjusted EBITDA (₹1,950–2,050 crore) — a ₹310 crore reduction from the LOI;
- A remediation escrow tied to the USFDA warning-letter closure (₹90 crore released on plant re-inspection);
- Vendor financing on the related-party receivable with 24-month repayment;
- A 100-day plan sequenced as: day 0–30 cash control & channel-inventory normalisation; day 30–60 KPI reset and R&D retention letters; day 60–100 plant remediation governance and synergy execution (procurement + back-office consolidation worth ₹24 crore annually).
Outcome
The fund went back to the seller with the adjusted case; after two rounds, they signed at 8.0x adjusted EBITDA — ₹310 crore below the original LOI — with the remediation escrow in place. Twelve months post-close, the domestic chronic franchise grew 13% as modelled, channel inventory normalised to 7.8 weeks, and the remediation plan was on track for re-inspection. The deal, which would have destroyed value at the LOI price, is on track for a 2.4x MOIC in the fund's base case.
Case study reconstructed for illustration from typical engagement patterns. Client and figures are hypothetical.
